Luca Pinello

Luca Pinello develops computational methods for analyzing CRISPR-based genetic interaction screens and single-cell perturbation experiments that identify synergistic gene-drug and drug-drug interactions in cancer cells, providing functional genomic evidence for combination therapy design. His research at Massachusetts General Hospital has created tools for analyzing how drug combinations affect chromatin accessibility and gene regulation at single-cell resolution, revealing the epigenomic mechanisms underlying drug synergy and resistance. His computational methods enable the systematic discovery of combination vulnerabilities through functional genomics approaches.